Visudyne Combo Therapies Are QLT’s Focus As Competition Comes Into View
QLT is working to position Visudyne as part of combination therapies for age-related macular degeneration in the face of stiffening competition
You may also be interested in...
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said
Concomitant use of Pfizer/Eyetech's Macugen (pegaptanib) with Novartis/QLT's Visudyne (verteporfin) does not pose safety concerns, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded Aug. 27
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011